FDA alignment secured as company prepares to begin dosing in 2026

Breakwater phase 3 data show significant gains in progression‑free survival

Sanofi therapy becomes first disability‑targeting medicine for nrSPMS

Final draft guidance recommends D‑VRd on the NHS in England and Wales

Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial

Study marks major milestone for CTH120 as company advances disease‑modifying ambitions

Guidance paves the way for NHS access for eligible adults in England and Wales

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

Partnership grants Lilly global rights to Alzstatin ACD680

Phase 3 results highlight metabolic benefits alongside weight loss